Table 5.

Diagnostic performance of the selected miRNA for CRC

miRNA	Diagnostic performance for CRC irrespective of cancer stage using tissue samples				Diagnostic performance for CRC irrespective of cancer stage using plasma samples				Diagnostic performance for early-stage CRC using plasma samples
	AUC	Cutoff point	Sensitivity	Specificity	AUC	Cutoff point	Sensitivity	Specificity	AUC	Cutoff point	Sensitivity	Specificity
miR-21-5p	0.78	3.56	0.80	0.83	0.78	3.89	0.81	0.83	0.77	3.69	0.80	0.81
miR-196b-5p	0.64	0.97	0.68	0.71	0.94	4.96	0.97	0.94	0.94	5.24	0.95	0.94
miR-135b-5p	0.76	2.32	0.80	0.83	0.83	1.45	0.86	0.89	0.84	2.05	0.85	0.88
miR-92a-3p	0.89	1.40	0.93	0.95	0.76	1.39	0.81	0.81	0.95	1.79	0.95	0.94
miR-29a-3p	0.81	1.23	0.85	0.83	0.83	1.21	0.86	0.83	0.87	0.41	0.90	0.88
miR-197-3p	0.52	2.41	0.56	0.63	0.60	2.06	0.61	0.67	0.76	2.41	0.80	0.81

miRNA (miR), microRNA; AUC, area under the receiver operating characteristic curve; CRC, colorectal cancer.